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Abstract
Malignant glioma belong to the most aggressive neoplasms in humans with no successful
treatment available. Patients suffering from glioblastoma multiforme (GBM), the highest-
grade glioma, have an average survival time of only around one year after diagnosis. Both
microglia and peripheral macrophages/monocytes accumulate within and around glioma,
but fail to exert effective anti-tumor activity and even support tumor growth. Here we use mi-
croarray analysis to compare the expression profiles of glioma-associated microglia/macro-
phages and naive control cells. Samples were generated from CD11b+ MACS-isolated cells
from naïve and GL261-implanted C57BL/6 mouse brains. Around 1000 genes were more
than 2-fold up- or downregulated in glioma-associated microglia/macrophages when com-
pared to control cells. A comparison with published data sets of M1, M2a,b,c-polarized mac-
rophages revealed a gene expression pattern that has only partial overlap with any of the
M1 or M2 gene expression patterns. Samples for the qRT-PCR validation of selected M1
and M2a,b,c-specific genes were generated from two different glioma mouse models and
isolated by flow cytometry to distinguish between resident microglia and invading macro-
phages. We confirmed in both models the unique glioma-associated microglia/macrophage
phenotype including a mixture of M1 and M2a,b,c-specific genes. To validate the expres-
sion of these genes in human we MACS-isolated CD11b+ microglia/macrophages from
GBM, lower grade brain tumors and control specimens. Apart from the M1/M2 gene analy-
sis, we demonstrate that the expression ofGpnmb and Spp1 is highly upregulated in both
murine and human glioma-associated microglia/macrophages. High expression of these
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genes has been associated with poor prognosis in human GBM, as indicated by patient sur-
vival data linked to gene expression data. We also show that microglia/macrophages are
the predominant source of these transcripts in murine and human GBM. Our findings pro-
vide new potential targets for future anti-glioma therapy.
Introduction
Malignant glioma (WHO grade III and IV), such as glioblastoma multiforme (GBM), are high-
ly aggressive and account for almost 50% of all brain neoplasms. As of today no successful
treatment exists, offering glioma patients an average survival time of about one year after diag-
nosis, despite surgical tumor resection, radio-, and chemotherapy [1]. Glioma are highly inva-
sive and the cellular and genetic inter- and intra-tumor heterogeneity has lead to the failure of
current anti-glioma therapy [2,3,4,5].
Among other immune cells, brain-resident microglia and peripheral macrophages/mono-
cytes are attracted toward glioma in large numbers and they can amount up to 30% of the cells
in the tumor tissue [6,7,8]. Experimental findings by us and others show that a tumoricidal ac-
tivity of glioma-associated microglia/macrophages (GAMs) is counteracted by the glioma cells,
which reprogram GAMs into tumor supportive cells. GAMs actively support tumor growth,
e.g. by secreting matrix-degrading enzymes as well as immunosuppressive factors [9,10,11,12].
Thus, these stromal cells might serve as an attractive target for anti-glioma therapy and the
identification of factors produced by GAMs might help to better understand disease progres-
sion [11,13,14,15,16].
Based on in vitro activation states macrophage polarization is divided into classical inflam-
matory (M1) activation (responsible for Th1 responses, type I inflammation, killing of intracel-
lular pathogens) and alternative (M2) activation. Alternative activation can be further divided
into M2a (Th2 responses, type II inflammation, killing of pathogens, allergy), M2b (Th2 activa-
tion, immunoregulation), and M2c (immunoregulation, matrix deposition, tissue remodeling)
activation [17]. Although the definition of these pure activation states is based on defined in
vitro conditions, and macrophage activation is likely to be much more diverse and complex in
the in vivo setting, several studies have addressed the expression of polarization marker genes
in GAMs, either in vitro or in vivo [9,13,18,19]. Similar to solid tumors in other organs, GAMs
produce factors associated with an alternative macrophage activation, such as increased pro-
duction of anti-inflammatory molecules (e.g. TGF-β1, ARG1, and IL-10), and molecules sup-
porting tissue remodeling and angiogenesis (e.g. VEGF, MMP2, MMP9, and MT1-MMP).
However, GAMs also produce pro-inflammatory molecules (e.g. TNF-α, IL1-β, and CXCL10)
[9,10,11,18,20,21]. To date no comprehensive comparison of GAMs expression pattern with
M1, M2a,b,c macrophages has been performed. In this study, we isolated CD11b+ cells from
GL261 mouse gliomas and naïve control mice and performed a genome-wide microarray ex-
pression analysis. We compared the GAMs expression profile to datasets of M1, M2a, M2b,
and M2c in vitro-stimulated macrophages. Using flow cytometry to distinguish between resi-
dent microglia and invading macrophages/monocytes, we investigated the expression of select-
ed genes in resident and invading GAMs in two different glioma mouse models by qRT-PCR.
To show the relevance for potential therapeutic applications, we investigated some key genes in
CD11b+ GAMs isolated from human GBM samples compared to cells isolated from lower
grade brain tumors, control microglia, and CD11b- cells in GBM. Last, we used the The Cancer
GAMsMicroarray M1 M2
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This study was carried out in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health. This study was ap-
proved by the local ethics committees for animal experiments: the Institutional Animal Care
and Use Committees of Cleveland Clinic, Lerner Research Institute – approved protocol num-
ber 2013-1029 (LRI, last approved June 25 2013) and the Committee on the Ethics of Animal
Experiments in Berlin (LaGeSo, Permit Numbers: GO 268-10, GO 343-10, GO 438-12). All
surgery was performed under anesthesia, and all efforts were made to minimize suffering.
Freshly resected patient samples were provided by the Department for Neurosurgery Char-
ité University Hospital and the Helios Clinics (both Berlin, Germany). Handling and analysis
of these tissues was performed according to the rules and with the approval of the Ethical
Committee and with patient’s written consents (Ethics Committee: “Ethikkommission der
Charité—Universitätsmedizin Berlin”, application number: EA4/098/11).
Animals
All in vivo work with GL261 glioma cells was done in C57BL/6 wild-type mice (Charles River
Laboratories, Wilmington, MA, USA). Age matched naïve C57BL/6 wild-type mice were used
as controls.
To broaden the relevance of our findings, we employed another murine model where the
tumor is initiated by the overexpression of PDGFb in Nestin-expressing cells in vivo: Ntv-a/
Ink4a-Arf-/- mice develop pro-neural high-grade gliomas 6 to 8 weeks following intracranial
injection of RCAS-PDGFb-producing DF-1 chicken fibroblast cells at 4.5 to 10 weeks of age
[22]. The genetic backgrounds of tv-a mice are FVB/N, C57BL/6, BALB/C, and tv-a. RCAS-
PDGFb tumors were dissociated as described below and intracranially re-transplanted into
Cx3cr1GFP/wt Ccr2RFP/wt mice (kind gift of Richard Ransohoff, [23]) to distinguish between
microglia and peripheral monocytes that invaded the brain. Naïve age-matched Cx3cr1GFP/wt
Ccr2RFP/wt mice were used as controls. 5 to 7 weeks after intracranial injection of RCAS tumor
cells into Cx3cr1GFP/wt Ccr2RFP/wt mice these mice develop tumors that are histologically identi-
cal to the original tumors in Ntv-a/Ink4a-Arf-/- mice.
Generation of intracranial mouse gliomas
Injections were performed using a stereotactic frame (Stoelting, Wood Dale, IL, USA). Mice
used for these experiments were 8 to 10-week-old (C57BL/6 mice for GL261 injection), 4.5 to
10-week-old (Ntv-a/Ink4a-Arf-/- mice for DF-1 RCAS-PDGFb injection), or 6–10-week-old
(Cx3cr1GFP/wt Ccr2RFP/wt mice for RCAS-PDGFb tumor cell re-implantation). Mice were anes-
thetized with intraperitoneal injections of ketamine (0.1 mg/g, Pharmazeutischen Handelsge-
sellschaft, Garbsen, Germany) and xylazine (0.02 mg/g, Bayer, Leverkusen, Germany).
Animals were also provided 0.25% Marcaine in the volume of about 0.1ml/25g administered
right before the surgery, which provided pain relief from the sutures for 6–8 hours.
One microliter cell suspension (2x104 GL261 cells, 4×104 transfected DF-1 cells, or 5x104
RCAS-PDGFb tumor cells) was delivered using a 30-gauge needle attached to a Hamilton sy-
ringe (Hamilton, Reno, NV, USA). Coordinates for GL261 injections into C57BL/6 mice were
bregma 1 mm anterior, Lat (lateral) -2 mm (right of midline), and a depth -3 mm from the
GAMsMicroarray M1 M2
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dural surface. Coordinates for injections of DF-1 cells, and RCAS-PDGFb tumor cells into Ntv-
a/Ink4a-Arf-/- mice, and Cx3cr1GFP/wt Ccr2RFP/wt mice, respectively were bregma 1.5 mm ante-
rior, Lat -0.5 mm, and a depth 2.0 mm. Mice were monitored daily for the first two weeks and
twice a day starting from day 15 post-injection for symptoms of tumor development (lethargy,
hydrocephalus, head tilting). The size of resulting tumors ranged from 1.5–2.5 mm (GL261 tu-
mors) and 2.5–3.5 mm (RCAS-PDGFb tumors).
Cultivation of Cell Lines
Cells of the murine GL261 glioma cell line (National Cancer Institute, MD, USA) were grown
in Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal calf serum (FCS), 200 mM
glutamine, 100 U/mL penicillin, and 100 mg/ml streptomycin (all from Invitrogen, Carlsbad,
CA, USA). DF-1 cells were purchased from ATCC (Manassas, VA, USA). Cells were grown at
39°C according to ATCC instructions. Transfections with RCAS-PDGFb were performed
using Fugene 6 transfection kit (no. 11814443001; Roche, Mannheim, Germany) according to
manufacturer’s protocol.
Tumorsphere Culture
RCAS-PDGFb tumors were excised from tumor brains using a scalpel, minced, and incubated
with Accutase (eBioscience, San Diego, CA, USA) for 15 minutes at 37°C. Tissue pieces were
mechanically dissociated using a 1 ml pipette and washed in Dulbecco modified Eagle medium
(DMEM; Sigma-Aldrich, St. Louis, MO, USA). Cells were passed through a 70 μm cell strainer
and seeded into a T25 cell culture flask. Cells were grown in GIC medium containing DMEM-
F12 GlutaMAX (GIBCO-Invitrogen, Carlsbad, CA, USA), 1% penicillin G/streptomycin sulfate
(Sigma-Aldrich), B-27 without vitamin A (1:50; GIBCO-Invitrogen), HEPES (0.2 mM, Sigma-
Aldrich), insulin (20 ng/ml, Sigma-Aldrich), supplemented with fibroblast growth factor
2 (FGF2, 20 ng/ml, Cell Systems, Kirkland, WA, USA) and epidermal growth factor (EGF,
20 ng/ml, Cell Systems).
Human tissue
Tumor and control tissue was taken during surgery while patients were under a general anes-
thetic, and was placed immediately in culture medium for transportation. Cells were isolated
from the tissue as described below no later than 2 hours after resection. Cell sorting was per-
formed via MACS isolation, using anti-CD11b microbeads (described below).
Cell Isolation
GL261-implanted mice were sacrificed 20 days post-injection, RCAS-PDGFb-implanted mice
were sacrificed 4–5 weeks post-injection. Tumor-bearing and control mice were euthanized by
i.p. injection of 200 μl pentobarbital-sodium (Narcoren, Pharmazeutischen Handelsge-
sellschaft) and perfused using a 0.9% NaCl solution. The brain and spleen were extracted and
stored in ice-cold HBSS (Gibco-Invitrogen). For naïve mouse brains, the olfactory bulbs and
the cerebellum were cut by a scalpel and discarded. The rest of the tissue was used for dissocia-
tion. In tumor-bearing mouse brains, only the visible tumor area around the injection site
was used.
Human and mouse tissue was dissociated with the Neural Tissue Dissociation Kit (Miltenyi
Biotec, Bergisch-Gladbach, Germany) according to the manufacturer’s instructions. To remove
the myelin we followed a protocol published elsewhere [24]. In brief, the brain cell suspension
was mixed with a total of 25 ml of a 22% Percoll (Th.Geyer, Renningen, Germany) solution
GAMsMicroarray M1 M2
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and a layer of 5 ml cold PBS (Gibco-Invitrogen) was added on top. Centrifugation at 950 g
with slow acceleration and without breaks created a gradient that separated the cell pellet on
the bottom of the tube from the myelin which was carefully aspirated. For the isolation of
GAMs from RCAS-PDGFb tumors-bearing and corresponding naïve Cx3cr1GFP/wt Ccr2RFP/wt
mice a 30%/70% Percoll gradient was used. After 25 min of centrifugation at 800 g GAMs and
naïve microglia were enriched at the 30%/70% interphase. Cells were collected, washed once
with PBS, and subsequently centrifuged again at 300 g for 10 min. Subsequently, the cell pellet
was resuspended in sorting buffer for subsequent magnetic-activated cell sorting (MACS) or
fluorescence-activated cell sorting (FACS) isolation.
Spleens were processed through a 70 μm cell strainer with a syringe plunger and the mesh
rinsed with 10 ml of PBS per spleen. The cells were centrifuged and the pellet subjected to
erythrocyte lysis by adding 5 ml of 1x RBC lysis buffer (Cat# 420301, Biolegend, San Diego,
CA, USA). The lysis was carried out by shaking the tube mildly for 5 min at RT and subse-
quently stopped with 20 ml of PBS. The pellet was washed once with PBS and resuspended in
PBS, containing 0.5% FCS and 2mM EDTA (FACS buffer) for subsequent FACS isolation.
For RCAS-PDGFb tumors blood monocytes were used as peripheral controls (instead of
monocytes isolated from spleens). To obtain blood monocytes, 200 μl of blood was mixed with
500 μl of PBS, containing 2.5 mM EDTA, centrifuged, the clear phase aspirated and the re-
maining phase mixed with 1 ml 1x RBC lysis buffer and incubated for 3 min on ice. The reac-
tion was stopped by adding PBS, cells were centrifuged, washed once in 1x RBC lysis buffer
and resuspended in FACS buffer.
MACS sorting
The CD11b+ samples for the microarray were generated using magnetic activated cell sorting
(MACS). Following percoll gradient centrifugation, tumor and control cell pellets were resus-
pended in PBS, containing 0.5% FCS and 2 mM EDTA and labeled with anti-CD11b microbe-
ads (Miltenyi Biotec, 130-093-634). The MACS isolation was carried out according to the
manufacturer’s instructions and cells were subsequently used for RNA isolation.
FACS sorting
Samples for qRT-PCR validation of target genes that were generated from GL261-bearing and
corresponding naïve control mice were FACS sorted using CD11b, CD45, Ly6C, and Ly6G
to distinguish between resident microglia (CD11b+/CD45low) and invading macrophages/
monocytes (CD11b+/CD45high/Ly6G-/Ly6Chigh). Following percoll gradient centrifugation,
cell pellets were resuspended in FACS buffer (containing 2% FCS) and stained with 2 μl of
dye-coupled antibodies per 1107 cells. The staining was done with CD45-e450 (48-0451-82),
Ly6G-PE (12-5931-82), Ly6C-PerCpCy5.5 (45-5932-82) and CD11b-APC (17-0112-82) (all
eBioscience, San Diego, CA, USA) for 30 min at 4°C. Thereafter, the cells were washed and re-
suspended in 500 μl FACS buffer per 5106 cells for sorting at a BD FACSAria II (BD Biosci-
ence). Compensation was calculated with single-stained beads (552844, BD Bioscience,
Franklin Lakes, NJ, USA) and unstained cells.
Samples generated from RCAS-PDGFb tumors were isolated without antibody staining.
Instead, tumor cells were reimplanted into Cx3cr1GFP/wt Ccr2RFP/wt mice which contain
RFP+/GFPlow macrophages/monocytes and RFP-/GFP+ microglia. Accordingly, fluorescence-
activated cell sorting was based on RFP and GFP positivity, in order to distinguish between res-
ident microglia and invading macrophages/monocytes. RFP+/GFPlow peripheral macrophages/
monocytes resemble the CD11b+/CD45high/Ly6G-/Ly6Chigh population. The RFP-/GFP+
microglia resemble the CD11b+/CD45low population.
GAMsMicroarray M1 M2
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RNA Protocols
Total RNA fromMACS or FACS-sorted cells was isolated using the RNeasy Plus Mini Kit
(Qiagen, Hilden, Germany). On-column DNase 1 (Qiagen) digestion was performed and total
RNA was eluted in RNase-free water. RNA yield was measured using a Nanodrop 1000 (Nano-
drop, Wilmington, DE, USA) spectrophotometer and quality was assessed using an Agilent
2100 Bioanalyzer (Agilent, Santa Clara, CA, USA). Samples were stored at -80°C until further
use. For qRT-PCR, first strand cDNA synthesis of RNA was done using the Superscript II
(Invitrogen) reverse transcriptase according to the manufacturer’s instructions. For mRNA
transcription oligo-dT primers (Invitrogen) were used. cDNA was stored at -20°C until
further processing.
Microarray
For the microarray MACS-isolated CD11b+ cells from GL261 gliomas (injected into 6–8-week-
old C57BL/6 mice; 3 samples; one tumor sample per RNA sample), and age-matched naïve
control mice (3 samples; three control brains were pooled per sample). We obtained yields of
500ng to 1 μg of total RNA of good quality (Agilent RNA Integrity Number, RIN = 8.2–10.0).
Sample preparation for microarray hybridization was carried out as described in the
Ambion WT Expression Kit Protocol (Life Technologies, Carlsbad, CA, USA) and the Affyme-
trix WT Terminal Labeling and Hybridization User Manual (Affymetrix, Inc., Santa Clara, CA,
USA). In brief, 300 ng of total RNA were used to generate double-stranded cDNA. 12 μg of
subsequently synthesized cRNA was purified and reverse transcribed into sense-strand (ss)
cDNA, whereat unnatural dUTP residues were incorporated. Purified ss cDNA was frag-
mented using a combination of uracil DNA glycosylase (UDG) and apurinic/apyrimidinic en-
donuclease 1 (APE 1) followed by a terminal labeling with biotin. 3,8 μg fragmented and
labeled ss cDNA were hybridized to Affymetrix Mouse Gene 1.0 ST arrays for 16 h at 45°C in a
rotating chamber. Hybridized arrays were washed and stained in an Affymetrix Fluidics Station
FS450, and the fluorescent signals were measured with an Affymetrix GeneChip Scanner 3000
7G.
Sample processing was performed at an Affymetrix Service Provider and Core Facility,
“KFB—Center of Excellence for Fluorescent Bioanalytics” (Regensburg, Germany; www.kfb-
regensburg.de). Data sets are available at http://www.ebi.ac.uk/arrayexpress under the acces-
sion number E-MTAB-2660.
Bioinformatic Analysis
Two additional data sets consisting of three samples each that were generated from CD11b+
MACS-isolated peritoneal myeloid cells were downloaded from http://www.ebi.ac.uk/
arrayexpress [25]—E-MEXP-3623; [26]—E-GEOD-25585) and used as peripheral controls.
Two independent approaches were used for bioinformatic data analysis. For the first method
the Affymetrix Expression Console Software Version 1.0 was used to create summarized ex-
pression values (CHP-files) from the expression array feature intensities (CEL-files). The Ro-
bust Multichip Analysis (RMA) algorithm was applied [27]. Integrative analysis of genome-
wide expression activities from DNA-microarray datasets was performed with the Gene Ex-
pression Dynamics Inspector (GEDI), a Matlab (Mathworks, Natick, MA) freeware program
which uses self-organizing maps (SOMs) to translate high-dimensional data into a 2D mosaic
[28]. Each tile of the mosaic represents an individual SOM cluster and is color-coded to repre-
sent high or low expression of the cluster's genes, thus identifying the underlying pattern.
For the second approach basal expression values (from CEL-files) were processed in R using
Bioconductor package Affy [29]. The Affy-scale-value-expression-set-function was set to 500
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and data was normalized with expresso-function, set to quantile normalization, and pmonly
correcte.method and medianpolish summary method. Gene annotation was done with mogen-
e10sttranscriptcluster [30], and only annotated probes were included in the analysis. Subse-
quently, collapseRows, was used to obtain a single representative probe for each gene, resulting
in 13,943 genes taken into the analysis [31]. Signed network analysis was done with Weighted
Gene Coexpression Network Analysis (WGCNA [32]). An adjacency network was made using
a softpower (β) value of 20, based upon the scale free criteria, and low connected genes were fil-
tered out of the analysis, resulting in 10,875 genes. Dendrogram formation and module deter-
mination was done by average linkage clustering and an arbitrary cut-off, determined by
WGCNA. From each module, the Module Eigengene (ME) was calculated, which is the first
principal component and functions as a representative of the expression profile of the module.
Next, as a measure for intramodular connectivity, the ME was correlated to the expression pro-
file of all intramodular genes, resulting in a kME-table, to determine which genes are most im-
portant, e.g. hub-genes. These module Membership values were multiple testing corrected
using R package Stats. Genes significantly associated to these modules (FDR p value<0.01)
were used for further analysis.
Heat maps were generated using heatmap.2 function of Bioconductor Package Gplots [33].
Functional annotation and transcription factor binding site enrichment analysis of the modules
was done using Webgestalt [34,35]. The WGCNA UserlistEnrichment method was used to de-
termine the significance of the overlap of several gene lists with the induced gene lists using a
Hypergeometric test [31].
For the Gene Set Enrichment Analysis (GSEA) the 438 upregulated genes from our GAMs
dataset were taken to form a gene set, and it was tested if this gene set is overrepresented in the
upregulated or downregulated genes in the M1 or M2a,b,c macrophage data sets in comparison
to M0. For each of M1, M2a, M2b, and M2c polarization, in total 4 runs of GSEA were execut-
ed. Taking M1 as an example, we fed the gene expression values of M1 and M0, each with 3
replicates, to the GSEA software; signal-to-noise ratios of each gene were calculated to rank the
genes in a descending manner. An enrichment score (ES) for the gene set of 438 genes was
then computed based on the gene ranking, which corresponds to the magnitude of the overrep-
resentation. Thereafter, the significance level of the ES was evaluated by a gene-set permutation
test with 1000 permutations.
qRT-PCR
Quantitative RT-PCR reactions were performed using the SYBR Select Mastermix (Applied
Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions on a 7500 Fast
Real-Time PCR System (Applied Biosystems).
Primers for target genes were designed to recognize all validated mRNA splice variants of
the gene, relying on the RefSeq sequences of the UCSC genome browser (http://genome.ucsc.
edu/). The primer sequences were generated using the Primer-Blast tool (http://www.ncbi.nlm.
nih.gov/tools/primer-blast/). Amplification of unintended targets was excluded by BLAST
search (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Calculation of unfavorable secondary struc-
tures and primer-dimer amplification was done with the IDT oligo analyzer (http://eu.idtdna.
com/analyzer/applications/oligoanalyzer/). For absolute quantification of target genes, nested
primers flanking the original primers were designed. Nested amplicons were purified from aga-
rose gels, and serial dilutions were used to generate standard curves for each gene. Primer se-
quences can be found in S1 Table.
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Survival outcome analysis
Cbioportal (http://www.cbioportal.org/public-portal/) was used to access patient survival in-
formation and tumor gene expression data of GBM patients (Study: Glioblastoma multiforme,
TCGA Provisional, mRNA Expression z-Scores (microarray), accessed in August 2014)
[36,37]. Subtype information was retrieved from [38]. The standard deviation of the gene ex-
pression values of all patients was calculated. Patients with a gene expression lower than the
negative standard deviation were clustered into the low expression group, whereas patients
with a gene expression higher than the positive standard deviation were clustered into the high
expression group. For subtype analysis the patients were clustered according to the standard
deviation of gene expression within that subtype. Survival plots were generated and Kaplan-
Meier curves were produced and statistical significances between high and low expression
groups were calculated with the Log Rank (Mantel-Cox) test using GraphPad Prism 5. To test
for a proportional risk increase with each unit of gene expression, we fitted a Cox proportional
hazards regression model to our data including a test for the proportional hazards assumption
[39]. Analysis was done using the statistical script language R [40].
Results
Gene expression profile of glioma-associated microglia/macrophages
(GAMs)
To identify glioma-regulated transcripts in glioma-associated microglia/macrophages, we iso-
lated microglia/macrophages from GL261 glioma-bearing brains using MACS sorting with
anti-CD11b antibodies. As controls we isolated microglia from age-matched healthy mouse
brain and performed an Affymetrix Genechip Mouse Gene 1.0ST microarray on these samples.
Additionally, we also used two data sets that were generated from CD11b+ MACS-isolated
peritoneal myeloid cells as peripheral controls. These data sets were downloaded from http://
www.ebi.ac.uk/arrayexpress [25]—E-MEXP-3623; [26]—E-GEOD-25585). The two additional
data sets consisted of three samples each, generated from either CD11b+ MACS-sorted [26] or
CD11b+MHC-IIhiB220-Gr1- flow-sorted cells [25]. When comparing the GAMs data set to the
three naïve control data sets, 783 genes were significantly upregulated at least 2-fold and 198
genes downregulated at least 2-fold (S2 Table).
We first applied the Gene Expression Dynamics Inspector (GEDI) on these datasets to visu-
alize the global patterns of gene expression in GAMs versus naive microglia and macrophages.
GEDI uses self-organizing maps to capture genome-wide transcriptome activity via ‘gestalt’
recognition [28]. GEDI facilitates the identification of genome-wide patterns with each mosaic
tile in the map representing a gene cluster that is expressed at similar levels. The four GEDI
maps, with blue colour indicating low and red colour high mRNA expression levels, show that
the gene expression patterns of GAMs and naive microglia are more similar to each other than
both macrophage datasets. Closer inspection of both microglia GEDI patterns then revealed a
central cluster of highly expressed genes in GAMs that is different from naive microglia (white
circle) (Fig. 1).
Weighted Gene Coexpression Network Analysis of the data sets
Using Weighted Gene Coexpression Network Analysis (WGCNA), we clustered genes into dif-
ferent modules, according to their co-expression pattern (Fig. 2). Within each module genes
were ranked according to how closely they correlated to the Eigengene expression of this mod-
ule (termed Module Membership). The Module Eigengene is the first principal component,
representing the gene expression patterns of all genes clustered into this module [41]. Two
GAMsMicroarray M1 M2
PLOSONE | DOI:10.1371/journal.pone.0116644 February 6, 2015 8 / 27
modules contained genes that were upregulated in glioma-associated samples compared to the
three control data set (labeled red and brown in Fig. 2). Table 1 shows the genes with the stron-
gest upregulation in GAMs and the modules they were clustered into. S3 Table lists all 10,875
genes and the corresponding modules they were clustered into.
In addition, the gene clustering revealed genes that were specific for either microglia or mac-
rophages. The orange module contains genes that were highly expressed in GAMs and already
showed high expression in naïve microglia, but low expression in naïve macrophages (Fig. 2).
Genes that showed high expression in GAMs and naïve macrophages, but low expression in
naïve microglia were clustered into the green module (Fig. 2). Two studies used RNA sequenc-
ing and microarray analysis to determine microglia and macrophage-specific genes [42,43].
Genes that were found to be microglia-specific in these reports predominantly clustered into
our orange module, whereas macrophage-specific genes are enriched in our green module, vali-
dating our findings.
We used Webgestalt to perform gene ontology (GO) enrichment analysis on all>2 fold
upregulated genes that clustered into the glioma-regulated (red and brown) modules (438
genes in total) to identify overrepresented GO terms (Table 2). Several GO terms were overrep-
resented in the GAMs data set that can be grouped into three main groups: regulation of im-
mune response/activation, programmed cell death, and response to other organism/to virus.
All genes included in the overrepresented GO terms are listed in S4 Table. Next, we used
Webgestalt to identify transcription factor binding sites that are enriched in the same set of
Fig 1. Graphical representation of gene expression patterns in the four data sets. The four GEDI maps
show that the gene expression patterns of GAMs and naive microglia are more similar to each other than both
macrophage datasets (blue colour indicating low and red colour high mRNA expression levels). The white
circle highlights a central cluster of highly expressed genes in GAMs that is different from naive microglia.
GAMs: glioma-associated microglia/macrophage microarray data; MG: naive microglia microarray data;
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genes (Table 3). This analysis revealed that enriched binding sites included known sites for
IRF1, IRF2, IRF7, IRF8, IRF9/STAT1/STAT2, STAT5A, STAT5B, and NFAT. Both Stat1 and
Stat2 clustered into the glioma-regulated brown module and were around 2.5 fold upregulated.
In contrast, Stat5a and Stat5b were not significantly regulated at the transcriptional level. Irf7
and Irf9 were 6.9-fold and 1.4-fold upregulated and clustered into the brown and red
module, respectively.
GAMs transcriptome only partially resembles an M1 or M2 polarization
To further analyze the phenotype of GAMs, we compared our glioma-associated data set with
typical markers for an M1 and M2 macrophage phenotype (Table 4). Furthermore, we com-
pared our data set with data sets of macrophages that were polarized in vitro into an M1 or
M2a,b,c phenotype. We used data sets (Data set: E-GEOD-32690; [44]) that contained data of
macrophages stimulated in vitro for 24 h with LPS and IFN-γ (M1 polarization), IL4 (M2a po-
larization), IFN-γ and complexed Ig (M2b polarization), and Dexamethasone (M2c polariza-
tion) – in comparison to unstimulated M0 macrophages.
For this analysis we considered genes in our GAMs dataset that were glioma-regulated
(genes that clustered into the red and brown module) and were>2-fold upregulated and
Fig 2. WGCNA gene clustering reveals glioma-regulated genemodules. Each color represents a different module and each module contains genes with
similar expression patterns over all four sample sets. The glioma-regulated modules (labeled as red and brown) were further analyzed, as they contained
genes that were upregulated in the glioma-associated set when compared to all three control sets. A third module (labeled as green module) contained genes
that were highly expressed in GAMs when compared to naïve microglia, but were already highly expressed in peripheral macrophages. The module that is
depicted as orange contains genes that were highly expressed in GAMs, and also highly expressed in naïve microglia, however expressed at lower levels in
peripheral macrophages. All other clusters contained genes that did not seem to be glioma-regulated.
doi:10.1371/journal.pone.0116644.g002
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compared them with genes that were>2-fold up- or downregulated in the four M1/M2a,b,c
data sets (in comparison to the M0 state). GAMs: 438 upregulated genes; M1: 1243 genes up-,
1704 genes downregulated; M2a: 227 genes up-, 322 genes downregulated; M2b: 501 genes up-,
483 genes downregulated; M2c: 381 genes up-, 358 genes downregulated. We found that all
gene sets are significantly enriched in our GAM profile, but the M1 and M2b subsets were
most significantly affected: M1 (138 out of 438 upregulated genes in GAMs were also upregu-
lated in M1 macrophages, 31.5%, Bonferroni p value: 2.01e-60), M2b-polarized macrophages
(80 out of 438 upregulated genes in GAMs were also upregulated in M2b macrophages, 18.3%,
p value: 5.29e-43). The enrichment of M2c- (34 out of 381 genes, 7.8%, p value: 1.62e-11) and
M2a (23 out of 438 genes, 5.3%, p value: 6.88e-09) was less strong (Fig. 3A). Table 5 lists all
genes that are significantly enriched in our GAMs data set and are specific for either M1, M2a,
M2b, or M2c polarization. Using Gene Set Enrichment Analysis (GSEA) we found that the 438
upregulated genes in GAMs are significantly enriched in the upregulated genes of all four mac-
rophage polarization sets (Fig. 3B). Furthermore we tested the enrichment of the>2 fold up-
and downregulated M1, M2a,b,c genes in the entire GAMs data set that resulted from the
WGCNA analysis (10,875 genes) (S1 Fig.). Six out of eight sets were significantly enriched in
the up- and downregulated genes of the GAMs data set. However, 59.6% of the genes that were
upregulated in GAMs (261 out of 438 genes) were not upregulated in any of the four
Table 1. The 25 highest-upregulated genes in the glioma-associated data set compared to all three control sets.
Log2 Expression
Gene Symbol Module P Value GAMs Naïve Microglia Control Mϕ1 Control Mϕ2 Fold Change
Gpnmb red 2.06E-07 12.63 7.26 7.60 7.51 36.02
Cxcl9 red 1.69E-08 12.83 7.63 7.14 8.67 32.27
Spp1 red 7.59E-06 12.31 7.92 7.84 6.88 27.24
Ly6i red 6.84E-09 11.55 6.94 6.79 7.07 24.48
Gjc3 red 1.41E-08 11.62 7.74 6.97 7.13 20.32
Il1r2 red 1.86E-06 11.64 8.22 7.03 6.99 18.70
Cd72 red 1.63E-06 12.13 8.81 7.63 7.42 18.04
Ms4a4c red 2.36E-07 12.11 7.72 8.00 8.15 17.76
Mmp13 red 2.34E-07 11.08 7.11 6.77 6.91 17.73
Serpina3n red 3.08E-08 11.71 8.18 7.17 7.39 17.45
Ptgs2 orange 0.001883 12.61 11.09 7.167 7.23 17.28
Gpr171 red 1.02E-07 11.23 7.20 7.21 7.24 16.12
Igfbp7 orange 0.00065 12.52 10.53 7.59 7.49 15.83
Il1b orange 0.001877 12.71 11.25 7.42 7.58 15.54
Ccl5 red 1.58E-10 12.46 9.02 8.00 8.64 15.03
Adamdec1 red 2.47E-07 10.69 6.75 6.81 6.84 14.78
Il1rn red 1.99E-10 11.63 8.03 7.46 7.77 14.76
Ifi44 red 3.59E-07 11.42 7.53 7.27 7.95 14.32
Spon1 red 4.10E-07 11.77 8.72 7.52 7.55 14.30
Acp5 brown 0.000145 12.38 7.74 9.24 8.88 13.58
Moxd1 red 4.40E-08 10.83 7.21 7.15 7.11 12.77
Trem1 red 7.96E-07 11.43 8.10 7.65 7.57 12.62
Gm6377 red 2.25E-06 11.14 8.45 7.05 7.02 12.40
Vcam1 orange 0.000315 11.76 9.95 7.19 7.36 12.12
Dnase1l3 brown 0.000265 10.98 6.91 7.68 7.66 11.84
doi:10.1371/journal.pone.0116644.t001
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macrophage phenotypes (Fig. 3C). This indicates that the GAMs phenotype shows only partial
overlap with the classical M1 or M2 macrophage phenotype.
Validation of M1 and M2a,b,c marker gene expression in GAMs
In addition we selected five genes that were upregulated in GAMs, clustered into the glioma-
regulated (red and brown) modules, and were specifically upregulated in either M1, M2a, M2b,
or M2c-polarized macrophages and validated the expression of these genes by qRT-PCR in
FACS-sorted samples. We selected Il1rn, Isg20 (both specific for M1-polarized macrophages),
Clec7a (M2a), Tgfbi (M2b), and Cxcr4 (M2c).
We FACS-isolated GAMs from GL261 tumors and RCAS-PDGFb tumors and measured
the expression by qRT-PCR in comparison to microglia and peripheral macrophages isolated
from control animals. For GAMs isolated from the GL261 mouse model, we distinguished be-
tween resident microglia (CD11b+/CD45low) and invading macrophages/monocytes (CD11b+/
CD45high/Ly6G-/Ly6Chigh) by FACS sorting (Fig. 4A; [45]). In addition to microglia derived
from naïve animals we also used spleen-derived macrophages/monocytes as
additional controls.
As a further validation we used the RCAS-PDGFb tumor model, which produces pro-neural
high-grade glioma, as a second glioma model system [22]. For this tumor model primary
RCAS-PDGFb tumors were re-transplanted into Cx3cr1GFP/wt Ccr2RFP/wt mice, which allowed
us to FACS-isolate RFP-/GFP+ microglia and RFP+/GFPlow macrophages/monocytes from tu-
mors, as well as RFP-/GFP+ microglia from control brains and RFP+/GFPlow monocytes from
peripheral blood without further antibody staining (Fig. 4B; [23]).
In the GL261 model a significant higher expression of all selected genes could be confirmed
in glioma-associated macrophages/monocytes and for Il1rn, Clec7a, and Cxcr4 in glioma-asso-
ciated microglia, compared to the respective control cells (Fig. 5).
Table 2. We used Webgestalt to identify overrepresented GO terms in >2 fold upregulated genes in
the glioma-regulated (red and brown) modules.
Biological process Number of genes Adjacent p value
Immune system process 102 genes adjP = 1.21e-30
Immune response 72 genes adjP = 9.65e-30
Defense response 68 genes adjP = 6.25e-23
Innate immune response 44 genes adjP = 6.25e-23
Response to biotic stimulus 53 genes adjP = 3.70e-22
Response to other organism 51 genes adjP = 5.91e-22
Immune effector process 45 genes adjP = 1.47e-18
Response to stress 106 genes adjP = 7.91e-18
Response to cytokine stimulus 40 genes adjP = 1.23e-17
Regulation of immune system process 57 genes adjP = 1.40e-17
Multi-organism process 55 genes adjP = 2.53e-16
Response to virus 25 genes adjP = 1.19e-13
Leucocyte activation 39 genes adjP = 2.52e-10
Cell activation 41 genes adjP = 7.62e-10
Programmed cell death 67 genes adjP = 1.24e-09
Cell death 69 genes adjP = 2.22e-09
doi:10.1371/journal.pone.0116644.t002
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In the RCAS model we saw a significant higher expression of all selected genes when com-
paring glioma-associated microglia to naïve microglia. When comparing glioma-associated
macrophages/monocytes to naïve monocytes, only the expression of Il1rn, Tgfbi, and Cxcr4
was significantly higher. For Isg20 we detected a lower expression in glioma-associated macro-
phages/monocytes when compared to naïve monocytes. Furthermore, the expression of Clec7a
was unchanged in glioma-associated macrophages/monocytes when compared to naïve mono-
cytes. All investigated genes were expressed at higher levels in naïve monocytes when compared
to naïve microglia. In part the expression was as high as in glioma-associated microglia. The dif-
ference of gene expression between the RCAS and the GL261 model might be partially caused by
the different isolation procedures. We used GFP/RFP expression in Cx3cr1GFP/wt Ccr2RFP/wtmice
for the RCAS model, as compared to antibody staining for CD11b/CD45/Ly6G/Ly6C in the
GL261 model.
Furthermore, the expression of the selected genes was lower in the RCAS model when com-
pared to the GL261 model – this was most notable for Isg20, Il1rn, and Clec7a. This might rep-
resent differences in the tumor biology of both models, but might also be owed to the different
growth pattern and kinetics of the tumors. Mice injected with GL261 tumors were sacrificed
20 days post-injection, whereas mice implanted with RCAS tumors were sacrificed 4–5 weeks
post-operation. Thus, GAMs in RCAS tumors were exposed to the tumor environment over
Table 3. We used Webgestalt to identify enriched transcription factor binding sites in >2 fold upregulated genes in the glioma-regulated (red
and brown) modules.
Enriched transcription factor targets Genes Statistics
mmu_STTTCRNTTT_V$IRF_Q6 Bst2, Ddr2, Dhx58, Dtx3l, Epsti1, Hgf, Ifi44, Ifit2, Ifit3, Il18bp, Isg15, Lgals3bp,
Nampt, Tap1, Tnfsf13b, Usp18, Xaf1, Zbp1
adjP = 2.16e-05
mmu_V$ISRE_01 Ammecr1, Bst2, Cxcr4, Dhx58, Dtx3l, Epsti1, Gpr65, Ifi44, Ifih1, Ifit2, Ifit3,
Isg15, Kynu, Met, Mmp25, Pgk1, Tnfsf13b, Usp18, Xaf1, Zbp1
adjP = 2.84e-05
mmu_V$ICSBP_Q6 Adam8, Bst2, Cxcr4, Dtx3l, Emp1, Ifi44, Ifih1, Ifit3, Il18bp, Isg15, Kynu,
Parp12, Tap1, Tfec, Tnfsf13b, Usp18, Zbp1, Zmynd15
adjP = 0.0004
mmu_V$IRF7_01 Bst2, Cxcr4, Dll4, Dtx3l, Epsti1, Ifit2, Il18bp, Isg15, Lgals3bp, Nr4a2, Nr4a3,
Parp12, Pdgfc, Tap1, Usp18, Xaf1, Zmynd15
adjP = 0.0012
mmu_V$IRF_Q6 Bst2, Cd80, Cxcr4, Dhx58, Dnase1l3, Dtx3l, Fcgr2b, Ifi44, Ifit2, Il18bp, Isg15,
Kynu, Parp12, Tnfsf13b, Ube2l6, Zbp1
adjP = 0.0026
mmu_V$IRF1_01 Bst2, Ccl5, Dnase1l3, Dtx3l, Isg15, Kynu, Neto1, Pdgfc, Slamf8, Tap1, Tfec,
Tgfb3, Tnfsf13b, Usp18, Xaf1
adjP = 0.0083
mmu_TTCYNRGAA_V$STAT5B_01 Ccl5, Cish, Crem, Dll4, Gzmb, Il18bp, Nfil3, Nkg7, Nr4a3, Pcolce, Plagl1, Plscr1,
Serping1, Socs2, Stc1, Tnfrsf9, Trim25
adjP = 0.0213
mmu_TGGAAA_V$NFAT_Q4_01 Adam9, Adamtsl4, Adm, Aig1, Arrdc4, Bhlhe40, Ccl5, Cd72, Cdkn1a, Chl1, Cish,
Creb5, Crem, Ctgf, Ctla4, Dab2, Ddr2, Dll4, Emp1, Erbb3, Gsn, Has2, Hgf, Hif1a,
Htr7, Htra4, Ifng, Igfbp3, Il1rn, Impa2, Inhba, Irs2, Isg15, Kynu, Lgals1, Mcam,
Mdfic, Mmp14, N4bp1, Nfil3, Nr4a2, Nr4a3, Pde4b, Pdk3, Pgam1, Plod2,
Prr11, Prrx1, Sema6a, Socs2, Spp1, Stc1, Tgfb3, Tmem97, Tnfsf10, Trim25, Vegfa
adjP = 0.0221
mmu_V$STAT5B_01 Ccl5, Cish, Crem, Dll4, Nfil3, Nr4a2, Nr4a3, Pcolce, Plagl1, Plscr1, Serping1, Socs2,
Stc1, Trim25
adjP = 0.0221
mmu_V$STAT5A_01 Ccl5, Cish, Crem, Dll4, Nfil3, Nr4a2, Nr4a3, Pcolce, Plagl1, Plscr1, Serping1, Socs2,
Stc1, Tnfrsf9
adjP = 0.0249
mmu_TGANTCA_V$AP1_C Adm, Aig1, Ass1, Atp6v0d2, Ccr7, Cd109, Cdkn1a, Creb5, Cst7, Emp1, Furin, Gpnmb,
Gpr141, Gzmb, Hspb6, Il10, Il1rn, Isg20, Itgax, Krt8, Lgals1, Mmp12, Mmp13, Mmp19,
N4bp1, Osmr, Plp2, Procr, Prrg4, Stat1, Stc1, Tm4sf19, Tnfrsf9, Trim25, Vat1, Vdr, Vegfa
adjP = 0.0460
mmu_V$STAT_01 Cish, Crem, Gzmb, Il18bp, Nfil3, Nkg7, Nr4a3, Pcolce, Plscr1, Runx3, Serping1, Socs2,
Trim25
adjP = 0.0460
mmu_V$IRF2_01 Bst2, Dnase1l3, Dtx3l, Pdgfc, Tap1, Tgfb3, Tnfsf13b, Usp18, Xaf1 adjP = 0.0460
doi:10.1371/journal.pone.0116644.t003
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longer times and the transcriptional program might have changed over the duration of
the stimulus.
Next, we collected human glioma samples and isolated CD11b+ microglia/macrophages via
MACS. We analyzed the gene expression of GAMs (CD11b+ sorted cells) in GBM samples, the
flow through of these tumor samples (the CD11b-negative fraction after MACS-isolation),
control microglia samples (taken from brain resections of hippocampus, epilepsy, and trauma
patients), and blood monocytes (Fig. 6).
We detected high expression of all genes in CD11b+ GAMs isolated from GBM samples,
however only the gene expression of IL1RN, ISG20 (both M1-specific), and TGFBI (M2b-spe-
cific) was significantly higher in CD11b+ cells isolated from GBM samples, when compared to
CD11b+ cells isolated from control brain samples. The expression of CXCR4 was not signifi-
cantly higher, whereas the expression of CLEC7A was significantly lower in CD11b+ cells iso-
lated from GBM samples. This might be in part due to the fact that the control brain specimen
Table 4. Expression of known M1, M2, and TAM marker genes in our GAMs data set.










Stat1 11.56 2.27 Tgm2 12.28 6.94 Cd204 11.87 13.55
Tlr2 11.29 2.51 Cd206 12.15 1.54 Stat3 11.67 1.42
Cd80 11.20 2.38 Cd204 11.87 13.55 Vegfr2 9.34 2.13
Cd86 11.13 2.03 Il1rII 11.63 1.72 Met 8.08 2.60
Tlr4 9.72 -1.33 Tlr8 11.00 3.21 Egfr 7.20 -1.52




Il1b 12.71 15.54 Il1rn 11.63 14.76 Arg1 11.48 3.91
Tnfa 11.03 2.89 Tgfb3 10.28 7.85 Mmp14 11.36 9.91
Nos2 10.14 7.24 Il10 8.96 3.76 Vegfa 11.34 8.35
Il18 9.33 1.71 Il6 8.32 1.90 Mmp13 11.08 17.73
Ifng 8.56 2.57 Tnfa 11.03 2.89
Il15 8.47 -1.36 Ctgf 10.53 5.35
Il23a 7.28 1.41 Arg2 10.43 11.37
Indol1 6.93 1.02 Mmp2 10.43 4.07





Chemokines Ccl3 13.21 7.93 Ccl17 8.84 2.47 Cxcl10 12.83 10.60
Cxcl9 12.82 32.27 Ccl24 8.05 -5.04 Ccl5 12.46 15.03
Ccl5 12.46 15.03 Ccl22 7.98 1.61 Cxcl16 12.18 5.94
Ccl2 11.15 4.86 Ccl1 6.86 1.22 Ccl17 8.84 2.47
Ccl9 11.03 -1.47 Ccl22 7.98 1.61
Ccl4 10.43 2.68 Cxcl12 7.01 -1.77
Ccl8 10.25 10.52 Ccl18 6.20 1.02
Ccl11 8.54 2.00
Marker genes were taken from literature reviews [10,17,65].
doi:10.1371/journal.pone.0116644.t004
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Fig 3. Comparison of GAMs with data sets of M1, M2a,b,c-stimulated macrophages.We retrieved data
sets from http://www.ebi.ac.uk/arrayexpress (Data set: E-GEOD-32690; [44]), containing data of
macrophages that were stimulated for 24 h in vitro into different polarization states (M0 (unstimulated), M1
(IFNγ + LPS), M2a (IL4), M2b (IFNγ + complexed Ig), and M2c (Dexamethasone)) and compared which
genes in these data sets significantly overlapped with glioma-regulated genes in our GAMs data set. A: A
graphical representation of the overlap of upregulated genes in GAMs and the four macrophage data sets.
The GAMs gene expression profile shows the greatest number of overlaps with M1, and M2b polarized
macrophages. B: Using Gene Set Enrichment Analysis (GSEA) we found that the 438 upregulated genes in
GAMs are significantly enriched in the upregulated genes of all four macrophage polarization sets. C: Only a
minority of genes upregulated in GAMs were also induced in the M1 to M2c phenotype, 59.5% of the genes
that were upregulated in GAMs were not regulated in any of the four macrophage phenotypes.
doi:10.1371/journal.pone.0116644.g003
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were not taken from healthy patients, but patients suffering from epilepsy (3 samples) and
trauma injury (1 sample). In these conditions the microglia might have already been polarized
toward an M2-like phenotype.
Table 5. M1 and M2a,b,c-specific genes that are >2-fold upregulated in our GAMs data set.
Genes
M1-specific 1500012F01Rik, 1600014C10Rik, Ahr, Arrdc4, BC023105, Best1, Bst2, C2, Car13, Ccr7, Cd200, Cd52, Clec4n, Clic4, Cpd, Crem,
D16Ertd472e, Ell2, Epsti1, Ero1l, Fmnl2, Gpr132, Gpr31c, Hmox1, Htra4, Ifi204, Ifih1, Il1rn, Inhba, Irf7, Isg20, Itga5, Kynu, Malt1, Mefv,
Met, Mmp14, Mmp25, Mxd1, Nos2, Nr1h3, Nr4a2, Oas3, Oasl2, Parp12, Plagl1, Ppa1, Procr, Pvr, Rab11fip1, Rasgrp1, Rnf213, Runx3,
Slamf7, Slfn5, Srxn1, Stat2, Timp1, Tiparp, Tnfaip2, Treml4, Trim25, Ube2l6, Zmynd15
M2a-
specific
Atp6v0d2, Clec7a, Itgax, Mmp13, Tnfrsf26, Vwf
M2b-
specific
AI504432, Casp12, Gpr171, Ifitm1, Il12rb2, Impa2, Itga1, Pdgfc, Plac8, Rspo1, Tgfb3, Tgfbi, Tmem171, Tnfsf13b, Vdr
M2c-
specific
Adamtsl4, Amica1, Arhgap19, Ctla2a, Cxcr4, Cyp4f18, Fbxo32, Gpr35, Gpx3, Il1r2, Ldlrad3, Mmp19, Wbp5
doi:10.1371/journal.pone.0116644.t005
Fig 4. Flow cytometry isolation strategies for generation of mouse qPCR samples. A) Plots depicting the strategy for isolation of microglia and
macrophages from naïve brains and GL261 glioma-bearing brains using antibody staining for CD11b, CD45, Ly6C, and Ly6G. CD45 staining was used to
distinguish between CD11b+/CD45low resident microglia (gate P9) and CD11b+/CD45high/Ly6G-/Ly6Chigh invading macrophages/monocytes (gates P8, P10,
and P11), which were mostly absent in naïve brain samples. B) GAMs from RCAS-PDGFb tumors were isolated relying on an antibody-independent
approach. Primary tumors from Ntv-a/Ink4a-Arf-/-mice were reimplanted intoCx3cr1GFP/wt Ccr2RFP/wtmice and GAMS were sorted according to GFP and
RFP expression. In naïve Cx3cr1GFP/wt Ccr2RFP/wtmice only GFP+ cells were present in the brain. In tumor-bearing mice, resident microglia were GFP+,
whereas invading macrophages/monocytes were RFP+/GFPlow or GFP+/RFP+. RFP+/GFPlow naïve blood monocytes were used as peripheral controls.
doi:10.1371/journal.pone.0116644.g004
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GAMs express the pro-tumorigenic genesGpnmb and Spp1
Two features of high grade glioma are the aggressive invasion into the brain parenchyma and
the immune-suppressive environment which prevents tumor rejection. Previously, we and
other groups reported the expression of several pro-tumorigenic genes expressed in GAMs. We
could confirm the expression of most of these genes in our dataset and a selection of these
genes can be found in Table 4.
To identify novel glioma-regulated genes expressed in microglia/macrophages that might
play a role in tumor-progression, we screened our dataset for genes that have been reported to
play a pro-tumorigenic role in peripheral tumors, but have not been reported in GAMs. The
genes Gpnmb and Spp1 were two of the highest upregulated genes in our GAMs data set
(Table 1), clustered into the glioma-regulated (red) module, and have been implicated in im-
mune-suppression (Gpnmb) or tumor cell invasion (Spp1) in peripheral tumors. To investigate
the expression of these genes in GAMs via qRT-PCR in FACS-sorted samples from GL261 and
RCAS-PDGFb tumors in comparison to naïve control cells we used the same samples as de-
scribed above for the validation of the M1 and M2a,b,c-specific genes.
We were able to validate the expression of both genes using qRT-PCR. Furthermore, the
regulation of the genes was similar in both brain tumor models – GL261, as well as RCAS-
PDGFb tumors (Fig. 7). This shows that the up-regulation of these genes was not specific for
Fig 5. qPCR validation of selected M1 and M2a,b,c-specific genes in murine GAMs.We selected 5 genes that were upregulated in GAMs and specific
for either M1 (Il1rn and Isg20), M2a (Clec7a), M2b (Tgfbi), or M2c polarization (Cxcr4) and investigated the expression of these using qRT-PCR. For this we
isolated GAMs from GL261 and RCAS-PDGFb tumors using flow cytometry, in order to distinguish between resident microglia and invading macrophages/
monocytes and used microglia, and spleen-derived macrophages/monocytes from naïve mice as controls. CTR MG: naïve microglia, CTR Mph: naïve
monocytes, TumMG: glioma-associated microglia, TumMph: glioma-associated macrophages/monocytes, GL261: cultured GL261 cells, TumMix: cultured
RCAS-PDGFb tumor cells. Bar graphs illustrate the absolute number of transcripts normalized to 100,000 transcripts of Actb (n = 4). Analysis was done by
students t test. Error bars indicate the Standard Error of Mean (SEM). *, p<0.05; **, p<0.01; ***, p<0.001
doi:10.1371/journal.pone.0116644.g005
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one tumor model, but was observed in two different independent models. In addition, the ex-
pression of both genes was higher in GAMs when compared to the tumor cells (except for
Gpnmb in the GL261 model), indicating that GAMs may be the primary source. Both genes
were differently expressed in glioma-associated microglia and macrophages, as invading mac-
rophages were the major source for Gpnmb in the RCAS-PDGFb model, whereas resident
microglia were the main source for Spp1 in both models. The expression level of Gpnmb in
both, glioma-associated resident microglia and invading macrophages/monocytes, was similar
in both glioma models. In contrast, the expression of Spp1 was stronger in resident microglia
and invading macrophages/monocytes isolated from RCAS-PDGFb tumors, when compared
to the GL261 model.
To investigate the difference of gene expression in GAMs in the GL261 and the RCAS-
PDGFb model in a broader set of genes we investigated the expression of six additional highly
upregulated genes that clustered into the red or brown module in both models (S2 Fig.). From
these six genes two were higher expressed in GAMs derived from the RCAS model (CD300lf
and Cd200r4), two genes were expressed at similar levels in GAMs in both tumor models
(Trem1 and Sh2d1b1), and two genes were higher expressed in GAMs derived from the GL261
model (Uck2 and Creb5).
Fig 6. qPCR validation of selected M1 and M2a,b,c-specific genes in human GAMs.We determined the expression of the M1 (IL1RN and ISG20), M2a
(CLEC7A), M2b (TGFBI), and M2c-specific (CXCR4) genes in CD11b+ and CD11b- cells isolated from human GBM (CD11b+ n = 13, CD11b- n = 5), control
brain (CD11b+ n = 5, CD11b- n = 2) and blood monocyte samples (n = 2). Bar graphs illustrate the absolute number of transcripts normalized to 100,000
transcripts of ACTB. Analysis was done by students t test. Error bars indicate the SEM. *, p<0.05; **, p<0.01; ***, p<0.001
doi:10.1371/journal.pone.0116644.g006
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Expression ofGPNMB and SPP1 is upregulated in human GBM-
associated microglia/macrophages
As described above, we collected human samples and isolated CD11b+ microglia/macrophages
via MACS and used qRT-PCR to determine the expression of GPNMB and SPP1 in these
Fig 7. Gpnmb and Spp1 expression is upregulated in murine GAMs. The gene expression ofGpnmb and
Spp1was validated using qRT-PCR. For this we used the same FACS-sorted samples from GL261 and
RCAS tumors as in Fig. 5. The upregulation of both genes could be confirmed in both tumor models. Resident
microglia and invading macrophages/monocytes show different expression patterns of these genes. CTR
MG: naïve microglia, CTR Mph: naïve monocytes, TumMG: glioma-associated microglia, TumMph: glioma-
associated macrophages/monocytes, GL261: cultured GL261 cells, TumMix: cultured RCAS-PDGFb tumor
cells. Bar graphs illustrate the absolute number of transcripts normalized to 100,000 transcripts of Actb (n =
4). Analysis was done by students t test. Error bars indicate the Standard Error of Mean (SEM). *, p<0.05;
**, p<0.01; ***, p<0.001
doi:10.1371/journal.pone.0116644.g007
Fig 8. GPNMB and SPP1 expression is upregulated in human GAMs.We determined the expression of the genesGPNMB and SPP1 in CD11b+ and
CD11b- cells isolated from human GBM (CD11b+ n = 15, CD11b- n = 9), meningioma (CD11b+ n = 5, CD11b- n = 3), grade III anaplastic astrocytoma
(CD11b+ n = 2, CD11b- n = 2), control brain (CD11b+ n = 5, CD11b- n = 2) and blood monocyte samples (n = 2). The expression ofGPNMB and SPP1was
significantly higher in CD11b+ cells isolated from GBMs compared to CD11b+ cells isolated from control brain, benign meningioma samples, blood
monocytes, and CD11b- cells in GBM. Bar graphs illustrate the absolute number of transcripts normalized to 100,000 transcripts of ACTB. Analysis was done
by students t test. Error bars indicate the SEM. *, p<0.05; **, p<0.01; ***, p<0.001
doi:10.1371/journal.pone.0116644.g008
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samples. In addition to CD11b+ and CD11b- cells isolated from GBM samples and naïve brain
tissue we also investigated meningioma and anaplastic astrocytoma (grade III glioma) samples.
We found that the expression of GPNMB and SPP1 was significantly higher in human
GAMs isolated from GBM samples, when compared to non-tumor-associated control micro-
glia and blood monocytes (Fig. 8). Furthermore, the expression of these genes was significantly
higher in GAMs than in the tumor flow through, indicating that GAMs are the predominant
source for these transcripts (S3 Fig.). The source and rate of expression of GPNMB seems to be
dependent on the grade of malignancy of the tumor. In GBM GAMs were the main source for
the expression, showing a 5 times higher expression than the GBM flow through, which com-
prises tumor cells and other stromal cells. However, when looking at meningioma, a benign
tumor of the meninges, the expression of GPNMB was higher in the CD11b- cell fraction, com-
pared to the CD11b+ cell fraction. The overall expression of GPNMB was higher in GBM than
in meningioma and grade III astrocytoma samples. The expression level of SPP1 was also de-
pendent on tumor grade. Similar to GPNMB, the expression of SPP1 was higher in GAMs iso-
lated from GBM specimen, compared to the GBM flow through. Whereas, in lower grade
tumors the expression of SPP1 was generally lower, which might indicate a possible role for
SPP1 in higher grade tumors.
High expression ofGPNMB and SPP1 in human GBM tissues is
associated with poorer survival outcome
We used the cBioPortal database (http://www.cbioportal.org/public-portal/), to access TCGA
data which links gene expression data to patient data, to investigate the effect of GPNMB and
SPP1 expression on patient prognosis [36,37]. We grouped patients into low and high expres-
sion (gene expression lower than the negative standard deviation or higher than the positive
standard deviation, respectively) and determined the overall survival for these patients. High
expression of each gene has a negative effect on patient prognosis. Median survival was 19.77
months (low GPNMB expression) vs. 12.92 months (high GPNMB expression) and 15.31
months (low SPP1 expression) vs. 8.82 months (high SPP1 expression) (Fig. 9). This
dataset also included G-CIMP+ tumors that are mostly proneural subtype tumors and generally
have a better overall survival prognosis when compared to G-CIMP- tumors. We excluded
these G-CIMP+ tumors from our analysis and reanalyzed the data. Most G-CIMP+ tumors ex-
hibited a low expression of both, GPNMB and SPP1. Accordingly, the overall survival predic-
tion for tumors with low expression of either GPNMB or SPP1 was less favorable after
removing G-CIMP+ tumors from the analysis. Median overall survival for GBM with low SPP1
or GPNMB expression was 14.16 months (low SPP1 expression including G-CIMP+ tumors) vs.
12.56 months (low SPP1 expression excluding G-CIMP+ tumors) and 17.7 months (low
GPNMB expression including G-CIMP+ tumors) vs. 14.82 months (low GPNMB expression
excluding G-CIMP+ tumors). We also plotted the overall survival of patients with intermediate
expression of each gene (S4 Fig.). Patients with high and intermediate GPNMB expression have
a similar overall survival prognosis, whereas patients with low GPNMB expression have a sig-
nificantly better prognosis. Median survival excluding G-CIMP+ tumors was 10.39 months
(high GPNMB expression), 9.84 months (intermediate expression), and 14.82 months (low ex-
pression). In contrast, the survival prognosis of patients with intermediate SPP1 expression is
in between of patients with low and high SPP1 expression. Median survival excluding G-
CIMP+ tumors was 7.29 months (high SPP1 expression), 10.49 months (intermediate expres-
sion), and 12.56 months (low expression).
In addition, we grouped patients into the four molecular subtypes (proneural incl. G-
CIMP+ tumors and w/o G-CIMP+ tumors, neural, mesenchymal, and classical) to investigate
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the effect of high GPNMB and SPP1 expression in these subtypes. Low GPNMB expression
is associated with the most positive effect on patient prognosis in the proneural subtype if
G-CIMP+ patients are included (p = 0.09, median survival of 20.66 months (low expression)
Fig 9. HighGPNMB and SPP1 expression is associated with worsened survival prognosis in human GBM patients.Data taken from the TCGA
database, showing survival probability of glioma patients grouped according to high and low expression of our target genesGPNMB (A) and SPP1 (B). High
expression of both genes has a negative effect on patient prognosis. Patients were in addition grouped into the four molecular subtypes (proneural, neural,
mesenchymal, and classical). LowGPNMB expression seems to have the most severe effect on patient prognosis in the proneural subtype when including
G-CIMP+ tumors, but no significant effect in the other subtypes. Low SPP1 expression seems to have the highest effect on patient prognosis in the neural and
classical subtypes. Furthermore, both genes are differently regulated in the four subtypes (box plots in A and B) Significances for box plots:GPNMB:
proneural GCIMP- (PG-) vs. proneural GCIMP+ (PG+) ***, PG- vs. mesenchymal (M) *** PG- vs. classical (C) **, PG+ vs. neural (N) ***, PG+ vs. M ***,
PG+ vs. C **, N vs. M ***, N vs. C *, M vs. C ***. SPP1: PG- vs. M ***, PG+ vs. N ***, PG+ vs. M ***, C vs. M ***.*, p<0.05; **, p<0.01; ***, p<0.001
doi:10.1371/journal.pone.0116644.g009
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vs. 9.21 months (high expression)), but not in the other subtypes. Low SPP1 expression is asso-
ciated with the most beneficial effect on patient prognosis in the neural (p = 0.044, median sur-
vival of 25.90 months vs. 5.65 months) and the classical subtype (p = 0.09, median survival of
15.31 months vs. 9.11 months). Furthermore, both genes are differently regulated within the
four subtypes. Mesenchymal tumors have a higher probability of high GPNMB and SPP1 ex-
pression, whereas classical tumors have a higher probability of low expression of both genes.
G-CIMP+ tumors, which generally have a better survival prognosis, display the lowest expres-
sion of both genes, indicating a possible role of these genes in advanced malignancy.
To test for a proportional risk increase for survival with the gene expression level, we fitted a
Cox proportional hazards regression model to our data including a test for the proportional
hazards assumption. The expression level of both genes had a significant effect on survival of
glioblastoma patients (all glioblastoma) when G-CIMP+ cases are included, as well as in the
proneural subtype when G-CIMP+ cases are included. All data sets, except neural subtype tu-
mors when tested for SPP1 expression, passed the test for the proportional hazards assumption
(S5 Table).
Discussion
Glioma-associated microglia/macrophages actively support glioma growth by the release of
factors that stimulate angiogenesis, invasion, or suppression of immunity [9,10,11,15]. In the
present study we performed a genome-wide expression analysis of these cells isolated from an
experimental glioma mouse model. We have identified genes which are specifically regulated
in glioma-associated microglia/macrophages when compared to naïve microglia or peripheral
macrophages. We selected some of these genes and validated their expression in two indepen-
dent glioma mouse models as well as in human glioma samples. In addition we could show
that the expression of these genes differs in microglia and macrophages/monocytes. Our results
are in accordance with previous reports that investigated the expression of selected target genes
in GAMs via qRT-PCR [9,10,11], and markers known for tumor-associated macrophages in
peripheral tumors. Several genes that are implicated in angiogenesis (Vegfa, Hgf), suppression
of immunity (Arg1, Tgfb3), and tumor invasion (Mmp2, Mmp14, Ctgf) were also highly ex-
pressed in our GAMs data set (Table 4).
Previous studies reported that GAMs express both markers of the M1 and M2 macrophage
phenotype [9,18]. However, no extensive comparison of these phenotypes has been performed
yet. By comparing our expression data with those generated from M1, M2a, M2b, and M2c-po-
larized macrophages, we show that the GAM phenotype shows only partial overlap with the
M1, M2a, M2b, and M2c phenotype. To date the term “M2-like polarization” has often been
used for describing the polarization of GAMs; our data indicate that GAMs do not fit into a
classical M1 or M2 phenotype, but represent a unique phenotype. As an alternate explanation
it might reflect heterogeneity among GAMs. One might speculate that dependent on the loca-
tion in the tumor tissue, some GAMs are polarized toward an M1-like phenotype, whereas
other GAMs possess a more M2-like phenotype and another population of GAMs is not polar-
ized toward M1 or M2-like states. Therefore, single-cell sequencing of GAMs would help to
better understand the activation status of GAMs.
GAMs have been shown to promote tumor growth, rather than inhibiting it, e.g. by secret-
ing factors that support glioma invasion or immunosuppressive factors [9,11,13,15]. Therefore,
these cells represent an attractive target for anti-glioma therapy, as modulation of their activa-
tion state might be useful to inhibit glioma progression [14,16]. Here we present GPNMB and
SPP1 as possible new targets and could show that these genes are highly expressed in GAMs in
different glioma mouse models, in human GBM, and that high expression of these genes is
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correlated with shorter glioma-patient survival. The expression of neither of these genes was
previously linked to GAMs.
The expression of GPNMB has been reported in tumor cells for different cancers, including
glioma [46,47]. Furthermore, GPNMB expression was detected in microglia of non-neoplastic
rat brains and increased with inflammation [48]. The data from our GL261 glioma model sug-
gests that GL261 cells express GPNMB at a very high level. However, in the RCAS-PDGFb glio-
ma mouse model, as well as in human GBM samples GAMs were the predominant source for
GPNMB expression in all tested paired samples (S3 Fig.). GPNMB (also called Osteoactivin) is
a transmembrane protein, but is also localized in the phagosome and can also be secreted, and
might have different functions in GAMs and in the tumor. Ripoll et al., have shown that
GPNMB acts as a negative regulator of pro-inflammatory macrophage activation in
RAW264.7 cells [49]. Thus, high GPNMB expression in GAMs could participate in the modu-
lation of the pro-tumorigenic phenotype of GAMs. Furthermore, GPNMB has been shown to
inhibit T cell activation via direct cell-cell interaction of antigen-presenting cells and T cells,
and could thus contribute to the immunosuppressive milieu in gliomas [50,51,52]. Finally,
anti-Gpnmb antibodies conjugated with a cytotoxic agent are under investigation for the treat-
ment of malignant glioma, breast cancer, and cutaneous melanoma [53,54,55].
Furthermore, we found that GAMs highly express SPP1. SPP1 (also called Osteopontin) is a
secreted protein that has been postulated to increase tumor cell invasion in vivo and migration
in vitro, and was found to be highly expressed in different types of cancers, such as lung cancer,
ovarian cancer, and also glioma [56,57,58,59,60,61]. Furthermore, SPP1 has recently been iden-
tified as a ligand for CD44. SPP1-CD44 interaction was shown to increase stemness of CD44-
expressing glioma-initiating cells [62]. Here we show that GAMs and not other cells of the
tumor microenvironment are the predominant source for SPP1 expression in glioma.
Two studies have previously performed screens of freshly-isolated GAMs. We used these
data sets to investigate the expression of Gpnmb, Spp1, Il1rn, Isg20, Cxcr4, Tgfbi, and Clec7a in
these studies (S6 Table). Huang et al., performed a screen of mouse GFP+ chimeric GL261-as-
sociated and naïve (also isolated from the brain) bone-marrow-derived myeloid cells. However,
using this approach they did not target the brain-resident microglia population that is also
present in the tumor (Data set: E-GEOD-38283) [63]. All of the investigated genes, except
Cxcr4, were also upregulated in our screen – however to a lesser degree. This was partially due
to an already high expression in the control cells. Furthermore, Murat et al., performed a mi-
croarray experiment on a paired sample of human GAMs and whole tumor lysate from the
same patient (Data set: GSE16119) [64]. All of the 7 genes were higher expressed in GAMs
when compared to the whole tumor lysate. However, it should also be noted that the whole
tumor lysate was not depleted of GAMs.
Taken together, our findings show that GAMs are polarized toward a phenotype that has
only partial overlap with the M1 or M2a, M2b, and M2c phenotypes. Furthermore, we identi-
fied GAMs as the predominant source for the pro-tumorigenic proteins GPNMB and SPP1 in
murine and human malignant glioma – highlighting the importance of macrophages and
microglia as therapeutic targets in anti-tumor treatment regimens.
Supporting Information
S1 Fig. GSEA analysis of the M1/M2a,b,c data sets against our GAMs data set.We per-
formed GSEA analysis of>2 fold up- and downregulated genes in M1/M2a,b,c vs. M0 macro-
phages against the entire GAMs data set that resulted from the WGCNA analysis.
(TIF)
GAMsMicroarray M1 M2
PLOSONE | DOI:10.1371/journal.pone.0116644 February 6, 2015 23 / 27
S2 Fig. The expression levels of six additional glioma-regulated genes. The expression of
Cd300lf, Cd200r4, Trem1, Sh2d1b1, Creb5, and Uck2 in flow-sorted glioma-associated micro-
glia and macrophages/monocytes isolated from mouse GL261 and RCAS-PDGFb tumors.
(TIF)
S3 Fig. GPNMB and SPP1 expression in CD11b+ and paired CD11b- fractions isolated
from human GBM samples.
(TIF)
S4 Fig. Kaplan-Meier curves of TCGA data of patients with high, intermediate, and low
GPNMB or SPP1 expression.
(TIF)
S1 Table. Primer sequences that were used for mouse and human qRT-PCRs and genera-
tion of nested amplicons.
(TXT)
S2 Table. List of all significantly up- and downregulated genes.
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S3 Table. Results of the WGCNA analysis. A list of all 10,875 genes that were used for
WGCNA analysis and the corresponding modules they were clustered into.
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S4 Table. All genes that were included in the overrepresented GO terms of the GAMs set.
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S5 Table. Results of the Cox proportional hazards regression model of the TCGA data for
GPNMB and SPP1.
(DOCX)
S6 Table. Comparison with other screens on GAMs. The expression values of Gpnmb, Spp1,
Il1rn, Isg20, Clec7a, Tgfbi, and Cxcr4 in our microarray screen and in two studies that per-
formed microarrays on GAMs are listed [63,64].
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